APP gains drug approval
Schaumburg-based APP Pharmaceuticals Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc., announced that it received approval from the U.S. Food and Drug Administration to market Indomethacin for injection.
APP will supply Indomethacin 1 mg as single dose vials. APP's Indomethacin is bar-coded, preservative-free and latex-free. According to IMS data, 2009 sales of this product in the United States were approximately $22.5 million.
The drug is used in neonates to treat patent ductus arteriosus, a common congenital heart defect.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.